Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240967 · ClinicalTrials.gov registry record · Phase 1
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01240967 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT01240967, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the absorption and distribution of a single oral dose of TC-5214 in subjects with renal impairment and with subjects with normal renal function.
Interventions
- DRUG TC-5214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240967
The ClinicalTrials.gov registry entry for NCT01240967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TC-5214 is the first listed.
NCT01240967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240967 about?
NCT01240967 is a clinical study titled "To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function". The purpose of this study is to compare the absorption and distribution of a single oral dose of TC-5214 in subjects with renal impairment and with subjects with normal renal function.
What is the current status of trial NCT01240967?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01240967?
The interventions under investigation include: TC-5214 (DRUG).
Who is sponsoring clinical trial NCT01240967?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.